Bio-Techne Corporation (TECH) — Analyst outlook / Analyst consensus target is. Based on 25 analyst ratings, the consensus is bullish — 18 Buy, 7 Hold.
The consensus price target is $69.33 (low: $62.00, high: $79.00), representing an upside of 18.2% from the current price $58.66.
Analysts estimate Earnings Per Share (EPS) of $1.78 and revenue of $1.16B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $1.07 vs est $1.78 (missed -39.9%). 2025: actual $0.47 vs est $1.90 (missed -75.2%). Analyst accuracy: 0%.
TECH Stock — 12-Month Price Forecast
$69.33
▲ +18.19% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Bio-Techne Corporation, the average price target is $69.33, with a high forecast of $79.00, and a low forecast of $62.00.
The average price target represents a +18.19% change from the last price of $58.66.
Highest Price Target
$79.00
Average Price Target
$69.33
Lowest Price Target
$62.00
TECH Analyst Ratings
Buy
Based on 25 analysts giving stock ratings to Bio-Techne Corporation in the past 3 months
EPS Estimates — TECH
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $1.07
vs Est $1.78
▼ 66.4% off
2025
Actual $0.47
vs Est $1.90
▼ 304.0% off
Profitability Outlook
Company is profitable but with thin earnings per share. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — TECH
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $1.159B
vs Est $1.159B
▲ 0.0% off
2025
Actual $1.220B
vs Est $1.216B
▲ 0.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
